HUS Diagnostic Center, HUSLAB, Department of Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):363-371. doi: 10.1007/s10096-021-04314-2. Epub 2021 Aug 5.
Rapid detection of pathogens causing bloodstream infections (BSI) directly from positive blood cultures is of highest importance in order to enable an adequate and timely antimicrobial therapy. In this study, the utility and performance of a recently launched next-generation fully automated test system, the Biofire FilmArray® Blood Culture Identification 2 (BCID2) panel, was evaluated using a set of 103 well-characterized microbial isolates including 29 antimicrobial resistance genes and 80 signal-positive and 23 signal-negative clinical blood culture samples. The results were compared to culture-based reference methods, MALDI-TOF, and/or 16S rDNA sequencing. Of the clinical blood culture samples, 68 were monomicrobial (85.0%) and 12 polymicrobial (15.0%). Six samples contained ESBL (bla), two MRSA (mecA), and three MRSE (mecA) isolates. In overall, the FilmArray BCID2 panel detected well on-panel targets and resistance markers from mono- and polymicrobial samples. However, one Klebsiella aerogenes and one Bacteroides ovatus were undetected, and the assay falsely reported one Shigella flexneri as Escherichia coli. Hence, the sensitivity and specificity for detecting microbial species were 98.8% (95%CI, 95.8-99.9%) and 99.9% (95%CI, 99.8-99.9%), respectively. The sensitivity and specificity for detecting of resistance gene markers were 100%. The results were available within 70 min from signal-positive blood cultures with minimal hands-on time. In conclusion, the BCID2 test allows reliable and simplified detection of a vast variety of clinically relevant microbes causing BSI and the most common antimicrobial resistance markers present among these isolates.
快速检测引起血流感染(BSI)的病原体直接从阳性血培养物中非常重要,以便能够进行适当和及时的抗菌治疗。在这项研究中,使用一组 103 种经过充分鉴定的微生物分离物评估了最近推出的下一代全自动测试系统,即 Biofire FilmArray®Blood Culture Identification 2(BCID2)面板,该系统包括 29 种抗生素耐药基因和 80 种信号阳性和 23 种信号阴性的临床血培养样本。结果与基于培养的参考方法、MALDI-TOF 和/或 16S rDNA 测序进行了比较。在临床血培养样本中,68 个为单一微生物(85.0%),12 个为多微生物(15.0%)。6 个样本中含有 ESBL(bla),2 个 MRSA(mecA)和 3 个 MRSE(mecA)分离物。总体而言,FilmArray BCID2 面板可很好地检测来自单一和多微生物样本的靶标和耐药标记物。然而,有一个肺炎克雷伯菌和一个卵形拟杆菌未被检测到,并且该检测错误地报告了一个福氏志贺菌为大肠埃希菌。因此,检测微生物物种的敏感性和特异性分别为 98.8%(95%CI,95.8-99.9%)和 99.9%(95%CI,99.8-99.9%)。耐药基因标记物的敏感性和特异性均为 100%。阳性血培养物的结果可在 70 分钟内获得,并且操作时间最少。总之,BCID2 测试允许可靠且简化地检测引起 BSI 的各种临床相关微生物以及这些分离物中最常见的抗生素耐药标记物。